Background/Aims: The etiology of IBD is unknown but may relate to an unidentified bacterial pathogen or an immunological reaction to gut microbiota. Antibiotics have therefore been proposed as a therapy for Crohn’s disease (CD) and ulcerative colitis (UC). The aim of this review was to compel the evidence for the use of antibiotics in the treatment of IBD. Methods: We performed a systematic review of the literature regarding the use of antibiotics for inducing or maintaining remission in IBD. Results: Current data are conflicting, but a recent systematic review of randomized controlled trials has shown a statistically significant effect of antibiotics being superior to placebo for active, perianal and quiescent CD and for active UC. These data have been poorly translated in clinical practice and the place of antibiotics is restricted to certain specific situations in the international guidelines. This is first linked to the difficulties in interpreting clinical trials because of their heterogeneity in study design, endpoints, type of antibiotic and concomitant therapies. The exception to this is the use of either ciprofloxacin or metronidazole for treating CD perianal fistulas. Conclusion: The pathology of CD, the likely primary and known secondary pathogens in this disease and the successful responses in animal models all plead for new trials of antibiotics in IBD. This is a call to select patients more carefully, and to continue antibiotics for longer than is customary. Beside antibiotics, new therapeutic approaches that can balance gut dysbiosis should be tested.

1.
Xavier RJ, Podolsky DK: Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007;448:427–434.
2.
Glasser AL, Boudeau J, Barnich N, Perruchot MH, Colombel JF, Darfeuille-Michaud A: Adherent invasive Escherichia coli strains from patients with Crohn’s disease survive and replicate within macrophages without inducing host cell death. Infect Immun 2001;69:5529–5537.
3.
Thompson AI, Lees CW: Genetics of ulcerative colitis. Inflamm Bowel Dis 2011;17:831–848.
4.
Gionchetti P, Rizzello F, Lammers KM, Morselli C, Tambasco R, Campieri M: Antimicrobials in the management of inflammatory bowel disease. Digestion 2006;73(suppl 1): 77–85.
5.
Isaacs KL, Sartor RB: Treatment of inflammatory bowel disease with antibiotics. Gastroenterol Clin North Am 2004;33:335–345.
6.
Perencevich M, Burakoff R: Use of antibiotics in the treatment of inflammatory bowel disease. Inflamm Bowel Dis 2006;12:651–664.
7.
Sartor RB: Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004;126:1620–1633.
8.
Biancone L, Michetti P, Travis S, Escher JC, Moser G, Forbes A, et al: European Evidence-Based Consensus on the Management of Ulcerative Colitis: special situations. J Crohns Colitis 2008;2:63–92.
9.
Dignass A, Van Assche G, Lindsay JO, Lemann M, Soderholm J, Colombel JF, et al: The Second European Evidence-Based Consensus on the Diagnosis and Management of Crohn’s Disease: current management. J Crohns Colitis 2010;4:28–62.
10.
Kornbluth A, Sachar DB: Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010;105:501–523; quiz 24.
11.
Lichtenstein GR, Hanauer SB, Sandborn WJ: Management of Crohn’s disease in adults. Am J Gastroenterol 2009;104:465–483; quiz 4, 84.
12.
Travis SP, Stange EF, Lemann M, Oresland T, Bemelman WA, Chowers Y, et al: European Evidence-Based Consensus on the Management of Ulcerative Colitis: current management. J Crohns Colitis 2008;2:24–62.
13.
Van Assche G, Dignass A, Reinisch W, van der Woude CJ, Sturm A, De Vos M, et al: The Second European Evidence-Based Consensus on the Diagnosis and Management of Crohn’s Disease: special situations. J Crohns Colitis 2010;4:63–101.
14.
Khan KJ, Ullman TA, Ford AC, Abreu MT, Abadir A, Marshall JK, et al: Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011;106:661–673.
15.
D’Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P: Early lesions of recurrent Crohn’s disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998;114:262–267.
16.
Rutgeerts P, Goboes K, Peeters M, Hiele M, Penninckx F, Aerts R, et al: Effect of faecal stream diversion on recurrence of Crohn’s disease in the neoterminal ileum. Lancet 1991;338:771–774.
17.
Baumgart DC, Sandborn WJ: Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007;369:1641–1657.
18.
Baumgart M, Dogan B, Rishniw M, Weitzman G, Bosworth B, Yantiss R, et al: Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn’s disease involving the ileum. ISME J 2007;1:403–418.
19.
Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser AL, Barnich N, et al: High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s disease. Gastroenterology 2004;127:412–421.
20.
Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR: Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA 2007;104:13780–13785.
21.
Neut C, Bulois P, Desreumaux P, Membre JM, Lederman E, Gambiez L, et al: Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn’s disease. Am J Gastroenterol 2002;97:939–946.
22.
Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M, et al: Mucosal flora in inflammatory bowel disease. Gastroenterology 2002;122:44–54.
23.
Tamboli CP, Neut C, Desreumaux P, Colombel JF: Dysbiosis in inflammatory bowel disease. Gut 2004;53:1–4.
24.
Pineton de Chambrun G, Colombel JF, Poulain D, Darfeuille-Michaud A: Pathogenic agents in inflammatory bowel diseases. Curr Opin Gastroenterol 2008;24:440–447.
25.
Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, Meyer zum Buschenfelde KH: Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995;102:448–455.
26.
Macpherson A, Khoo UY, Forgacs I, Philpott-Howard J, Bjarnason I: Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 1996;38:365–375.
27.
Podolsky DK: Inflammatory bowel disease. N Engl J Med 2002;347:417–429.
28.
Kobayashi KS, Chamaillard M, Ogura Y, Henegariu O, Inohara N, Nunez G, et al: Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005;307:731–734.
29.
Travassos LH, Carneiro LA, Ramjeet M, Hussey S, Kim YG, Magalhaes JG, et al: Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat Immunol 2010;11:55–62.
30.
Wehkamp J, Harder J, Weichenthal M, Schwab M, Schaffeler E, Schlee M, et al: NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal alpha-defensin expression. Gut 2004;53:1658–1664.
31.
Sartor RB: Targeting enteric bacteria in treatment of inflammatory bowel diseases: why, how, and when. Curr Opin Gastroenterol 2003;19:358–365.
32.
Bamias G, Marini M, Moskaluk CA, Odashima M, Ross WG, Rivera-Nieves J, et al: Down-regulation of intestinal lymphocyte activation and Th1 cytokine production by antibiotic therapy in a murine model of Crohn’s disease. J Immunol 2002;169:5308–5314.
33.
Fiorucci S, Distrutti E, Mencarelli A, Barbanti M, Palazzini E, Morelli A: Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis. Digestion 2002;66:246–256.
34.
Hoentjen F, Harmsen HJ, Braat H, Torrice CD, Mann BA, Sartor RB, et al: Antibiotics with a selective aerobic or anaerobic spectrum have different therapeutic activities in various regions of the colon in interleukin 10 gene deficient mice. Gut 2003;52:1721–1727.
35.
Madsen KL, Doyle JS, Tavernini MM, Jewell LD, Rennie RP, Fedorak RN: Antibiotic therapy attenuates colitis in interleukin 10 gene-deficient mice. Gastroenterology 2000;118:1094–1105.
36.
Onderdonk AB, Hermos JA, Dzink JL, Bartlett JG: Protective effect of metronidazole in experimental ulcerative colitis. Gastroenterology 1978;74:521–526.
37.
Rath HC, Schultz M, Freitag R, Dieleman LA, Li F, Linde HJ, et al: Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect Immun 2001;69:2277–2285.
38.
Videla S, Vilaseca J, Guarner F, Salas A, Treserra F, Crespo E, et al: Role of intestinal microflora in chronic inflammation and ulceration of the rat colon. Gut 1994;35:1090–1097.
39.
Yamada T, Deitch E, Specian RD, Perry MA, Sartor RB, Grisham MB: Mechanisms of acute and chronic intestinal inflammation induced by indomethacin. Inflammation 1993;17:641–662.
40.
Borgaonkar MR, MacIntosh DG, Fardy JM: A meta-analysis of antimycobacterial therapy for Crohn’s disease. Am J Gastroenterol 2000;95:725–729.
41.
Afdhal NH, Long A, Lennon J, Crowe J, O’Donoghue DP: Controlled trial of antimycobacterial therapy in Crohn’s disease. Clofazimine versus placebo. Dig Dis Sci 1991;36:449–453.
42.
Arnold GL, Beaves MR, Pryjdun VO, Mook WJ: Preliminary study of ciprofloxacin in active Crohn’s disease. Inflamm Bowel Dis 2002;8:10–15.
43.
Graham DY, Al-Assi MT, Robinson M: Prolonged remission in Crohn’s disease following therapy for Mycobacterium paratuberculosis infection. Gastroenterology 1995;108:A826.
44.
Leiper K, Martin K, Ellis A, Watson AJ, Morris AI, Rhodes JM: Clinical trial: randomized study of clarithromycin versus placebo in active Crohn’s disease. Aliment Pharmacol Ther 2008;27:1233–1239.
45.
Lochs H, Prantera C, Gionchetti P, Danese S, Fogli MV, Grimaldi M: A new extended intestinal release formulation of rifaximin, 400 mg tablets, for the treatment of moderately active Crohn’s disease. Gastroenterology 2011;140(5 suppl 1):S-572.
46.
Prantera C, Kohn A, Mangiarotti R, Andreoli A, Luzi C: Antimycobacterial therapy in Crohn’s disease: results of a controlled, double-blind trial with a multiple antibiotic regimen. Am J Gastroenterol 1994;89:513–518.
47.
Prantera C, Lochs H, Campieri M, Scribano ML, Sturniolo GC, Castiglione F, et al: Antibiotic treatment of Crohn’s disease: results of a multicentre, double-blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther 2006;23:1117–1125.
48.
Selby W, Pavli P, Crotty B, Florin T, Radford-Smith G, Gibson P, et al: Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn’s disease. Gastroenterology 2007;132:2313–2319.
49.
Steinhart AH, Feagan BG, Wong CJ, Vandervoort M, Mikolainis S, Croitoru K, et al: Combined budesonide and antibiotic therapy for active Crohn’s disease: a randomized controlled trial. Gastroenterology 2002;123:33–40.
50.
Sutherland L, Singleton J, Sessions J, Hanauer S, Krawitt E, Rankin G, et al: Double blind, placebo controlled trial of metronidazole in Crohn’s disease. Gut 1991;32:1071–1075.
51.
Bernstein LH, Frank MS, Brandt LJ, Boley SJ: Healing of perineal Crohn’s disease with metronidazole. Gastroenterology 1980;79:357–365.
52.
Dejaco C, Harrer M, Waldhoer T, Miehsler W, Vogelsang H, Reinisch W: Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn’s disease. Aliment Pharmacol Ther 2003;18:1113–1120.
53.
Ursing B, Kamme C: Metronidazole for Crohn’s disease. Lancet 1975;1:775–777.
54.
Maeda Y, Ng SC, Durdey P, Burt C, Torkington J, Rao PK, et al: Randomized clinical trial of metronidazole ointment versus placebo in perianal Crohn’s disease. Br J Surg 2010;97:1340–1347.
55.
Thia KT, Mahadevan U, Feagan BG, Wong C, Cockeram A, Bitton A, et al: Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn’s disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis 2009;15:17–24.
56.
West RL, van der Woude CJ, Hansen BE, Felt-Bersma RJ, van Tilburg AJ, Drapers JA, et al: Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn’s disease with infliximab: a double-blind placebo-controlled study. Aliment Pharmacol Ther 2004;20:1329–1336.
57.
Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F, Aerts R, et al: Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection. Gastroenterology 1995;108:1617–1621.
58.
Rutgeerts P, Van Assche G, Vermeire S, D’Haens G, Baert F, Noman M, et al: Ornidazole for prophylaxis of postoperative Crohn’s disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2005;128:856–861.
59.
Doherty GA, Bennett GC, Cheifetz AS, Moss AC: Meta-analysis: targeting the intestinal microbiota in prophylaxis for post-operative Crohn’s disease. Aliment Pharmacol Ther 2010;31:802–809.
60.
Burke DA, Axon AT, Clayden SA, Dixon MF, Johnston D, Lacey RW: The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment Pharmacol Ther 1990;4:123–129.
61.
Chapman RW, Selby WS, Jewell DP: Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut 1986;27:1210–1212.
62.
Dickinson RJ, O’Connor HJ, Pinder I, Hamilton I, Johnston D, Axon AT: Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut 1985;26:1380–1384.
63.
Gilat T, Suissa A, Leichtman G, Delpre G, Pavlotzky M, Grossman A, et al: A comparative study of metronidazole and sulfasalazine in active, not severe, ulcerative colitis. An Israeli multicenter trial. J Clin Gastroenterol 1987;9:415–417.
64.
Gionchetti P, Rizzello F, Ferrieri A, Venturi A, Brignola C, Ferretti M, et al: Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. Dig Dis Sci 1999;44:1220–1221.
65.
Mantzaris GJ, Archavlis E, Christoforidis P, Kourtessas D, Amberiadis P, Florakis N, et al: A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis. Am J Gastroenterol 1997;92:454–456.
66.
Mantzaris GJ, Hatzis A, Kontogiannis P, Triadaphyllou G: Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am J Gastroenterol 1994;89:43–46.
67.
Mantzaris GJ, Petraki K, Archavlis E, Amberiadis P, Kourtessas D, Christidou A, et al: A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. Scand J Gastroenterol 2001;36:971–974.
68.
Ohkusa T, Kato K, Terao S, Chiba T, Mabe K, Murakami K, et al: Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter trial. Am J Gastroenterol 2010;105:1820–1829.
69.
Ohkusa T, Nomura T, Terai T, Miwa H, Kobayashi O, Hojo M, et al: Effectiveness of antibiotic combination therapy in patients with active ulcerative colitis: a randomized, controlled pilot trial with long-term follow-up. Scand J Gastroenterol 2005;40:1334–1342.
70.
Turunen UM, Farkkila MA, Hakala K, Seppala K, Sivonen A, Ogren M, et al: Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology 1998;115:1072–1078.
71.
Abdelrazeq AS, Kelly SM, Lund JN, Leveson SH: Rifaximin-ciprofloxacin combination therapy is effective in chronic active refractory pouchitis. Colorectal Dis 2005;7:182–186.
72.
Gionchetti P, Rizzello F, Venturi A, Ugolini F, Rossi M, Brigidi P, et al: Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther 1999;13:713–718.
73.
Isaacs KL, Sandler RS, Abreu M, Picco MF, Hanauer SB, Bickston SJ, et al: Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis 2007;13:1250–1255.
74.
Madden MV, McIntyre AS, Nicholls RJ: Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig Dis Sci 1994;39:1193–1196.
75.
McLaughlin SD, Clark SK, Tekkis PP, Ciclitira PJ, Nicholls RJ: An open study of maintenance antibiotic therapy for chronic antibiotic-dependent pouchitis: efficacy, complications and outcome. Colorectal Dis 2011;13:438–444.
76.
Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, et al: Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment Pharmacol Ther 2002;16:909–917.
77.
Sandborn WJ: Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment. Gastroenterology 1994;107:1856–1860.
78.
Sandborn WJ, Pardi DS: Clinical management of pouchitis. Gastroenterology 2004;127:1809–1814.
79.
Shen B, Achkar JP, Lashner BA, Ormsby AH, Remzi FH, Brzezinski A, et al: A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis 2001;7:301–305.
80.
Shen B, Remzi FH, Lopez AR, Queener E: Rifaximin for maintenance therapy in antibiotic-dependent pouchitis. BMC Gastroenterol 2008;8:26.
81.
Kyne L, Farrell RJ, Kelly CP: Clostridium difficile. Gastroenterol Clin North Am 2001;30:753–777.
82.
Goodhand JR, Alazawi W, Rampton DS: Systematic review: Clostridium difficile and inflammatory bowel disease. Aliment Pharmacol Ther 2011;33:428–441.
83.
Dial S, Kezouh A, Dascal A, Barkun A, Suissa S: Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection. CMAJ 2008;179:767–772.
84.
Gaia E, Pais P, Salacone P, Morello C: Preliminary results obtained with cefoperazone plus corticosteroids in the treatment of active Crohn’s disease. Inflamm Bowel Dis 2009;15:1123–1124.
85.
Feller M, Huwiler K, Schoepfer A, Shang A, Furrer H, Egger M: Long-term antibiotic treatment for Crohn’s disease: systematic review and meta-analysis of placebo-controlled trials. Clin Infect Dis 2010;50:473–480.
86.
Shafran I, Kugler L, El-Zaatari FA, Naser SA, Sandoval J: Open clinical trial of rifabutin and clarithromycin therapy in Crohn’s disease. Dig Liver Dis 2002;34:22–28.
87.
McLaughlin SD, Clark SK, Shafi S, Petrovska L, Tekkis PP, Ciclitira PJ, et al: Fecal coliform testing to identify effective antibiotic therapies for patients with antibiotic-resistant pouchitis. Clin Gastroenterol Hepatol 2009;7:545–548.
88.
Greenberg GR: Antibiotics should be used as first-line therapy for Crohn’s disease. Inflamm Bowel Dis 2004;10:318–320.
89.
Isaacs KL, Lewis JD, Sandborn WJ, Sands BE, Targan SR: State of the art: IBD therapy and clinical trials in IBD. Inflamm Bowel Dis 2005;11(suppl 1):S3–S12.
90.
Boulos A, Rolain JM, Raoult D: Antibiotic susceptibility of Tropheryma whipplei in MRC5 cells. Antimicrob Agents Chemother 2004;48:747–752.
91.
Fedorak RN, Madsen KL: Probiotics and prebiotics in gastrointestinal disorders. Curr Opin Gastroenterol 2004;20:146–155.
92.
Fedorak RN, Madsen KL: Probiotics and the management of inflammatory bowel disease. Inflamm Bowel Dis 2004;10:286–299.
93.
Roberts CL, Keita AV, Duncan SH, O’Kennedy N, Soderholm JD, Rhodes JM, et al: Translocation of Crohn’s disease Escherichia coli across M-cells: contrasting effects of soluble plant fibres and emulsifiers. Gut 2010;59:1331–1339.
94.
Barnich N, Carvalho FA, Glasser AL, Darcha C, Jantscheff P, Allez M, et al: CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease. J Clin Invest 2007;117:1566–1574.
95.
Carvalho FA, Barnich N, Sivignon A, Darcha C, Chan CH, Stanners CP, et al: Crohn’s disease adherent-invasive Escherichia coli colonize and induce strong gut inflammation in transgenic mice expressing human CEACAM. J Exp Med 2009;206:2179–2189.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.